

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

*Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or any state securities laws of the United States, and may not be offered or sold in the United States unless registered under the U.S. Securities Act and the applicable securities laws of any state or other jurisdiction of the United States or pursuant to an exemption from, or in a transaction not subject to, registration under the U.S. Securities Act and the applicable securities laws of any state or other jurisdiction of the United States. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.*



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

**COMPLETION OF PLACING OF NEW SHARES
UNDER GENERAL MANDATE**

Placing Agents

(in alphabetical order)



Reference is made to the announcement of the Company dated August 5, 2020 (the “**Announcement**”) in relation to, among other matters, the Placing. Unless defined otherwise, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

COMPLETION OF THE PLACING

The Board is pleased to announce that completion of the Placing took place on August 12, 2020.

A total of 498,753,118 new Shares, representing approximately 3.71% of the total issued share capital of the Company as at the date of this announcement (as enlarged by the allotment and issue of the Placing Shares), have been successfully placed to not less than six Placees at a price of HK\$20.05 per Placing Share.

To the best of the Company’s knowledge, information and belief, and having made all reasonable enquiries, (i) the Placing Agents, the Placees and their respective ultimate beneficial owners are Independent Persons; and (ii) none of the Placees have become a substantial shareholder of the Company immediately after the completion of the Placing.

EFFECT ON SHAREHOLDING STRUCTURE

Based on the information available to the Company, set out below is the shareholding structure of the Company as at the date of this announcement (i) immediately before the completion of the Placing and (ii) immediately after completion of the Placing:

Shareholder	As at the date of this announcement immediately before completion of the Placing		As at the date of this announcement immediately after completion of the Placing	
	No. of Shares	Percentage of issued share capital	No. of Shares	Percentage of issued share capital
Perfect Advance Holding Limited ⁽¹⁾⁽³⁾	3,103,816,661	23.96%	3,103,816,661	23.08%
Innovare Tech Limited ⁽²⁾⁽³⁾	1,078,837,347	8.33%	1,078,837,347	8.02%
Ali JK Nutritional Products Holding Limited ⁽⁴⁾	4,560,785,407	35.21%	4,560,785,407	33.91%
Antfin (Hong Kong) Holding Limited ⁽⁵⁾	60,576,000	0.47%	60,576,000	0.45%
Directors of the Company or its subsidiaries	12,904,818	0.10%	12,904,818	0.09%
Placees	—	—	498,753,118	3.71%
Other Shareholders	<u>4,134,662,691</u>	<u>31.93%</u>	<u>4,134,662,691</u>	<u>30.74%</u>
Total	<u><u>12,951,582,924</u></u>	<u><u>100.00%</u></u>	<u><u>13,450,336,042</u></u>	<u><u>100.00%</u></u>

Notes:

- (1) Perfect Advance Holding Limited (“**Perfect Advance**”) is wholly-owned by Alibaba Investment Limited, which is in turn wholly-owned by Alibaba Holding.
- (2) Innovare Tech Limited (“**Innovare**”) is wholly controlled by Yunfeng Fund II, L.P., which is a direct wholly-owned subsidiary of Yunfeng Investment II, L.P. and an indirect wholly-owned subsidiary of Yunfeng Investment GP II, Ltd. Yunfeng Investment GP II, Ltd. is owned by Mr. Ma Yun as to 40% and Mr. Yu Feng as to 60%.
- (3) On October 12, 2018, Innovare and Perfect Advance entered into a shareholders’ agreement which constitutes a concert party agreement for the purpose of section 317(1)(a) of the SFO, pursuant to which Perfect Advance enjoys a right of first refusal over the 1,078,837,347 Shares held by Innovare.
- (4) Ali JK Nutritional Products Holding Limited is owned by Alibaba Holding as to 100%.
- (5) On July 12, 2019, 60,576,000 Shares were allotted to Antfin (Hong Kong) Holding Limited (“**Antfin**”) pursuant to a subscription agreement entered into between the Company and Antfin on May 23, 2019.

For and on behalf of the Board
Alibaba Health Information Technology Limited
ZHU Shunyan
Chairman and Chief Executive Officer

Hong Kong, August 12, 2020

As at the date of this announcement, the Board comprises eight Directors, of which (i) two are executive Directors, namely Mr. ZHU Shunyan and Mr. WANG Qiang; (ii) three are non-executive Directors, namely Mr. WU Yongming, Mr. WANG Lei and Mr. XU Hong; and (iii) three are independent non-executive Directors, namely Mr. LUO Tong, Mr. WONG King On, Samuel and Ms. HUANG Yi Fei (Vanessa).